poisar

Stocks · News reference

Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate

BenzingaBenzinga Newsdesk

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.88) by 2.27 percent. This is a 2.27 percent decrease over losses of $(0.88) per share

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dianthus Therapeutics granted equity awards to six newly-hired, non-executive employees on October 1, 2026. The inducement grants consist of non-qualified stock options to purchase 106,000 shares of common stock with an exercise price of $88.32 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.